Based on external evaluation, the Faculty of Medicine has approved the following nine Research programs. All programs are approved for six years. Some of the programs will have a a mid-term written review at the end of 2021.
Applied Tumor Genomics (ATG)
Group leader: Lauri Aaltonen
16 members (9 Principal Investigators, 4 Associated Clinical Researchers, 3 Junior Researchers)
Clinical and Molecular Metabolism (CAMM)
Group leader: Kirsi Pietiläinen
26 members (10 Principal Investigators, 11 Associated Clinical Researchers, 5 Junior Researchers)
Human Microbiome Research
Group leader: Willem de Vos
19 members (7 Principal Investigators, 9 Associated Clinical Researchers, 3 Junior Researchers)
Individualized Drug Therapy (INDIVIDRUG)
Group leader: Mikko Niemi
15 members (11 Principal Investigators, 3 Associated Clinical Researchers, 1 Junior Researchers)
Program in Translational Immunology (TRIMM)
Group leader: Satu Mustjoki
23 members (10 Principal Investigators, 11 Associated Clinical Researchers, 2 Junior Researchers)
Sleep and stress in health and in transition from acute to chronic diseases (SLEEPWELL)
Group leader: Tiina Paunio
14 members (8 Principal Investigators, 4 Associated Clinical Researchers, 2 Junior Researchers)
Systems Oncology (ONCOSYS)
Group leader: Sampsa Hautaniemi
19 members (10 Principal Investigators, 6 Associated Clinical Researchers, 3 Junior Researchers)
Translational Cancer Medicine Program (CAN-PRO)
Group leader: Kari Alitalo
19 members (12 Principal Investigators, 2 Associated Clinical Researchers, 5 Junior Researchers)
Translational Stem Cell Biology and Metabolism (STEMM)
Group leader: Timo Otonkoski
16 members (11 Principal Investigators, 4 Associated Clinical Researchers, 1 Junior Researchers)
Altogether twelve research program candidates participated in the scientific evaluation. The negotiations on space allocations and other resources will take place in the fall 2018 with the chosen nine Research Programs.